TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01756495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod
Description: Wet granulation formulation, Film coated white, 7 mm round, biconvex, plain faced Tablet of 7.5 mg or 10 mg unit dose strength. Taken orally 7.5 mg BID / 20 mg QD for 5 days in one of the 4 study periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod
Description: Wet granulation formulation, Film coated white, 7 mm round, biconvex, plain faced Tablet of 7.5 mg or 10 mg unit dose strength. Taken orally 7.5 mg BID / 20 mg QD for 5 days in one of the 4 study periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 17.2mm x 7.1 mm capsule shaped pink biconvex tablet of 400 mg unit dose strength. Taken orally 400 mg on Day 5 in one of the 4 study periods

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Losmapimod matched Placebo
Description: Direct compression formulation (visually matched to GW856553), Film coated white, 7 mm round, biconvex, plain faced Tablet. Taken orally for 5 days in one of the 4 study periods

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin Placebo
Description: 16 mm x 8 mm capsule shaped to white film coated tablet. Taken orally for 5 days in one of the 4 study periods
Study: NCT00620828

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo saline injection
Description: 20 cc of sterile, injectable saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine 0.5%
Description: Ropivicaine
Study: NCT03948256

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Prompt closure of EVD with subsequent observation period

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Description: Gradual weaning of EVD with 5 cmH2O increase in drainage resistance daily until complete closure with subsequent observation period
Study: NCT03475381

Intervention type: DRUG
Intervention: Ivacaftor+lumacaftor
Description: 1 year follow-up after initiation of ivacaftor+lumacaftor
Study: NCT00071760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW433908
Description: Fosamprenavir suspension bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW433908
Description: Fosamprenavir suspension bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Ritonavir solution bid
Study: NCT00403247

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsule with folate, Vitamin B12 & pyridoxine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule
Study: NCT02429518

Intervention type: DRUG
Intervention: Miltefosine
Study: NCT01075698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-ARB (standard therapy)
Description: Blood pressure lowering therapy except ARB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARB (Telmisartan)
Description: Telmisartan 20-80 mg/day
Study: NCT00362908

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Fat and Moderate Carbohydrate Diet
Description: 40% allowable fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Fat and Moderate Carbohydrate Diet
Description: 40% allowable fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
Study: NCT00362908

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat and High Carbohydrate Diet
Description: 20% fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat and High Carbohydrate Diet
Description: 20% fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
Study: NCT01830439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824 200mg
Description: Two single administrations of 200mg PA-824 each administered by four 50mg tablets, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824 200mg
Description: Two single administrations of 200mg PA-824 each administered by four 50mg tablets, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
Study: NCT04259684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gases Nitric Oxide (gNO)
Description: Participants in the intervention group will receive gNO blended into the fresh gas flow of the cardiopulmonary bypass (CPB) oxygenator and maintained at 20 ppm via an Ikaria INO Max DSIR (Mallinckrodt Pharmaceuticals, St. Louis, Missouri, USA), with continuous sampling of NO and NO2 concentration from a port adjacent to the oxygenator. The gNO delivery will be initiated when the patient is on CPB and stopped once the patient comes off CPB.
Study: NCT03688555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-774312
Description: ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo hard gelatin capsules
Study: NCT04578925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Happy, Healthy, Loved
Description: A text message based, mobile-device delivered intervention that provides educational information to primiparous mothers and their partners about breast-feeding and coping with stress.
Study: NCT03365531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate Daily Fasting (ADF)
Description: See ADF arm for details
Study: NCT01339117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fermentable substrate diet
Description: Diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fermentable substrate diet
Description: Diet high in fermentable oligosaccharides, disaccharides, monosaccharides and polyols
Study: NCT04316000

Intervention type: OTHER
Intervention: Initial Anxiety and Fear of Cancer Test
Description: Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) before the initial endoscopic procedure.

Intervention type: OTHER
Intervention: Initial Anxiety and Fear of Cancer Test
Description: Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) before the initial endoscopic procedure.

Intervention type: OTHER
Intervention: Initial Anxiety and Fear of Cancer Test
Description: Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) before the initial endoscopic procedure.

Intervention type: PROCEDURE
Intervention: Endoscopic band ligation without resection of the subpetihelial tumour.
Description: Correct application of the elastic band in the subepithelial tumor, achieving its removal by self-amputation in the 4-6 weeks endoscopic ultrasonography (EUS) control.

Intervention type: OTHER
Intervention: 1-2 Months Anxiety and Fear of Cancer Test
Description: Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1-2 months of the initial endoscopic procedure, knowing whether the tumor has either been removed or not, is a benign entity or has not been observed.

Intervention type: OTHER
Intervention: 1-2 Months Anxiety and Fear of Cancer Test
Description: Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1-2 months of the initial endoscopic procedure, knowing whether the tumor has either been removed or not, is a benign entity or has not been observed.

Intervention type: OTHER
Intervention: 1-2 Months Anxiety and Fear of Cancer Test
Description: Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1-2 months of the initial endoscopic procedure, knowing whether the tumor has either been removed or not, is a benign entity or has not been observed.

Intervention type: OTHER
Intervention: 1 Year Anxiety and Fear of Cancer Test
Description: Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1 year of the initial endoscopic procedure, knowing whether the tumor has either been removed or not.

Intervention type: OTHER
Intervention: 1 Year Anxiety and Fear of Cancer Test
Description: Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1 year of the initial endoscopic procedure, knowing whether the tumor has either been removed or not.
Study: NCT03365531

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Restriction (CR)
Description: See CR arm for details
Study: NCT04185415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bepranemab
Description: bepranemab will be administered in a predefined dosage.~* Pharmaceutical Form: Solution for infusion~* Route of Administration: Intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical Form: Solution for infusion~* Concentration: 0.9% w/v sodium chloride aqueous solution~* Route of Administration: Intravenous
Study: NCT02680470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual observed therapy
Description: Virtual Observation of participants taking their medication
Study: NCT02759224

Intervention type: DRUG
Group type: OTHER
Intervention: BRI-1501

Intervention type: DRUG
Group type: OTHER
Intervention: BRI-1501

Intervention type: DRUG
Group type: OTHER
Intervention: Lafutidine

Intervention type: DRUG
Group type: OTHER
Intervention: Lafutidine

Intervention type: DRUG
Group type: OTHER
Intervention: Irsogladine maleate

Intervention type: DRUG
Group type: OTHER
Intervention: Irsogladine maleate
Study: NCT05481099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Cognitive-behavioural-based intervention combined with mindfulness (attention focus), psychoeducation, and relaxation techniques (short version of Jacobson's progressive relaxation, breathing exercises)
Study: NCT01528761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prosocial Behavior Physical Activity (PBPA)
Description: The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
Study: NCT03388957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: This drug will be given before the extraction procedure
Study: NCT01528761

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Aging (HA)
Description: The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
Study: NCT02077543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain Tissue Imprint - Medical Device (ProTool)
Description: genomic, transcriptomic and proteomic studies.
Study: NCT02314364

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT with protons or photons
Study: NCT03181295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized exercise Rx and resources
Description: Patients will receive the IPAQ to collect baseline PA levels as well as questions evaluating precursors to behaviour change and identifying medical conditions that may affect PA capability. In the Electronic Medical Record chart, a 'stamp' will be automatically created, accompanied by a link which will open a printable 'toolkit' with individualized PA recommendations, a personalized exercise Rx, as well as educational and community resources, all based on the patient's survey responses. The exercise Rx and resources can be edited by the PCP based on the resulting discussion between patient and PCP, and printed during the PHR for the patient to take home. The exercise Rx and resources will also be emailed to the patient following their appointment.
Study: NCT01830439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824 50mg
Description: Two single administrations of 50mg PA-824 each administered by one 50mg tablet, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824 50mg
Description: Two single administrations of 50mg PA-824 each administered by one 50mg tablet, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
Study: NCT02496923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen therapy (Optiflow™)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen therapy (Hudson Type face mask or nasal prongs)
Study: NCT01187043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: 1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: 1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: 1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: 1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: 1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)
Study: NCT03345589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-22mg/kg/d Ursodeoxycholic
Description: 18-22mg/kg/d Ursodeoxycholic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 13-15mg/kg/d Ursodeoxycholic
Description: 13-15mg/kg/d Ursodeoxycholic
Study: NCT00335972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
Study: NCT03860129

Intervention type: DRUG
Group type: OTHER
Intervention: Isoflurane
Description: Group A: Isoflurane (0.5 MAC)

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: Group B: Sevoflurane (0.5 MAC)

Intervention type: DRUG
Group type: OTHER
Intervention: Desflurane
Description: Group C: Desflurane (0.5 MAC)
Study: NCT00620139

Intervention type: BIOLOGICAL
Intervention: the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,
Description: patient will undergo transoral pretreatment biopsy of the tumor. A comparable second tumor biopsy will be performed in the office after exactly 5 days of concurrent CRT (5 daily fractions of 180-200 cGy radiotherapy and a single cycle of Cisplatin or Carboplatin/5-FU based chemotherapy).Blood plasma and single-void urine specimens will be collected contemporaneously,before and after 5 days of concurrent CRT.
Study: NCT00719693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-143 ( rosuvastatin calcium and fenofibric acid )
Description: one dose under low-fat meal condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-143 (rosuvastatin calcium and fenofibric acid )
Description: one dose under fasting meal condition
Study: NCT02211443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant full human Anti-EGFR Monoclonal Antibody
Study: NCT02110342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] PF-04449913
Description: Single oral dose of 100 mg PF-04449913 + 100µCi of \[14C\] PF-04449913
Study: NCT01612494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: intravenous formulation of 3% hypertonic saline in a bolus dose of 10ml/kg over one hour

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: intravenous formulation of normal saline in a bolus dose of 10ml/kg over one hour
Study: NCT04449185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days
Description: Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days
Study: NCT03742791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-134
Description: 5 mg to 80 mg oral solution
Study: NCT04843748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cataract surgery and intraocular lens implantation - both eyes
Description: cataract surgery and intraocular lens implantation for both eyes
Study: NCT01741181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplementation
Description: Vitamin D3 marketed by oneNine57

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill
Description: Placebo pill supplied by oneNine 57 imported to Singapore with approval and import licence from HSA.
Study: NCT04804397

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose
Description: Sucrose sweetened soft drinks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose sweetened soft drinks
Study: NCT00457782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2478
Description: Daily intravenous KW-2478 for 5 days in 14-day cycles, ascending dose cohorts
Study: NCT02581904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena Care
Description: The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry gauze dressing care
Description: Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry gauze dressing care
Description: Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
Study: NCT02706535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762 Besylate Tablets
Description: GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762 Besylate Tablets
Description: GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762 Besylate Tablets
Description: GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: Itraconazole is available as a clear yellow solution with unit dose strength of 10 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: Itraconazole is available as a clear yellow solution with unit dose strength of 10 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin 300 mg
Description: Rifampicin is available as a red capsule with printed markings and as a 300 mg unit dose strength.
Study: NCT01503567

Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionaire

Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionaire

Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionaire

Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionaire
Study: NCT04343937

Intervention type: PROCEDURE
Intervention: retrolaminar block
Description: local anesthetic injection on the between the lamina of the vertebra and the paraspinous muscle
Study: NCT04333628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chloroquine
Description: oral treatment of chloroquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chloroquine
Description: oral treatment of chloroquine

Intervention type: OTHER
Group type: OTHER
Intervention: standard care
Description: Currently, there is no specific treatment for novel coronavirus. The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
Study: NCT03195231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wuling Powder
Description: Patients of Wuling Group are instructed to take Wuling Powder 3 times a day and 3 pills each time for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients of Placebo Group are instructed to take placebo drug 3 times a day and 3 pills each time for 12 weeks.